EQS-News

PAION AG enters partnership with Viatris and expands sales activities in Europe - Seite 2

PAION chose to partner with Viatris to leverage its Global Healthcare Gateway to bring to the market their novel, innovative therapies in the area of Anesthesia and Critical Care and provide more access at scale for patients in Europe.


About PAION

PAION AG is a publicly listed specialty pharmaceutical company with innovative compounds for use in outpatient and hospital sedation, anaesthesia and intensive care. PAION's lead compound is Remimazolam, an intravenously administered, ultra-short acting and highly controllable benzodiazepine sedative and anaesthetic. PAION has started the commercialisation of Remimazolam (Byfavo) in selected European markets. Remimazolam is partnered in several markets outside Europe. Remimazolam is approved in the US, EU/EEA/UK, China and South Korea for short sedation and in Japan, China and South Korea for general anaesthesia. 

In addition, PAION markets two products for critical care in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor for the treatment of refractory hypotension in adults with septic or other distributive shock, and Eravacycline (XERAVA), a novel fluorocycline antibiotic for the treatment of complicated intra-abdominal infections in adults.

PAION's mission is to be a leading specialty pharmaceutical company in the fields of anaesthesia and critical care by bringing novel products to market that benefit patients, physicians and other healthcare stakeholders.

PAION is headquartered in Aachen, Germany. 


PAION contact:

Investor Relations
cometis AG
Thorben Burbach
Tel.: [phone]
E-Mail: [e-mail]
www.paion.com


Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG’s management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.